| Identification | Back Directory | [Name]
Dual Specificity Protein Phosphatase 1/6 Inhibitor | [CAS]
15982-84-0 | [Synonyms]
NSC 150117
(E/Z)-BCI (NSC150117)
(E/Z)-BCI(DUSP6 inhibitor)
Dual Specificity Protein Phosphatase 1/6 Inhibitor
1H-Inden-1-one, 3-(cyclohexylamino)-2,3-dihydro-2-(phenylmethylene)- | [Molecular Formula]
C22H23NO | [MDL Number]
MFCD20232928 | [MOL File]
15982-84-0.mol | [Molecular Weight]
317.42 |
| Chemical Properties | Back Directory | [Boiling point ]
484.6±45.0 °C(Predicted) | [density ]
1.15±0.1 g/cm3(Predicted) | [storage temp. ]
Keep in dark place,Sealed in dry,2-8°C | [solubility ]
DMSO: 63 mg/mL (198.48 mM);Ethanol: 20 mg/mL (63.01 mM) | [form ]
solid | [pka]
7.74±0.20(Predicted) | [color ]
yellow | [Water Solubility ]
Water: Insoluble |
| Hazard Information | Back Directory | [Uses]
(E/Z)-BCI (NSC 150117) is a dual-specificity phosphatase 6 (DUSP6) inhibitor with anti-inflammatory activities. (E/Z)-BCI attenuates LPS-induced inflammatory mediators and ROS production in macrophage cells via activating the Nrf2 signaling axis and inhibiting the NF-κB pathway[1]. | [in vivo]
(E/Z)-BCI hydrochloride (35 mg/kg; intraperitoneal injection; every 7 days; for four weeks; female BALB/c nude mice) treatment enhances cisplatin efficacy in PDX models[2]. | Animal Model: | Patient-derived xenograft (PDX) models (4-5-week-old female BALB/c nude mice)[2] | | Dosage: | 35 mg/kg | | Administration: | Intraperitoneal injection; every 7 days; for four weeks | | Result: | Tumor weights in the PDX models treated plus CDDP were significantly suppressed compared with tumors from PDX model mice treated with either agent alone.
|
| [storage]
Store at -20°C | [References]
[1] Zhang F, et al. DUSP6 Inhibitor (E/Z)-BCI Hydrochloride Attenuates Lipopolysaccharide-Induced Inflammatory Responses in Murine Macrophage Cells via Activating the Nrf2 Signaling Axis and Inhibiting the NF-κB Pathway. Inflammation. 2019 Apr;42(2):672-681. DOI:10.1007/s10753-018-0924-2
[2] Wu QN,et al. Pharmacological inhibition of DUSP6 suppresses gastric cancer growth and metastasis and overcomes cisplatin resistance. Cancer Lett. 2018 Jan 1;412:243-255. DOI:10.1016/j.canlet.2017.10.007 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|